as 11-15-2024 4:00pm EST
Stocks
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
| Founded: | 1998 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 65.0M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 150.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.32 - $6.45 | Next Earning Date: | 11-26-2024 |
| Revenue: | $572,291 | Revenue Growth: | 2.32% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
The information presented on this page, "PTHL Pheton Holdings Ltd Class A Ordinary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.